# Safety, Tolerability, and Pharmacokinetics of Andecaliximab in Adults With Chronic Obstructive Pulmonary Disease (COPD)

> **NCT02077465** · PHASE1 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 11 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** Andecaliximab
- **DRUG:** Placebo to match Andecaliximab

## Key facts

- **NCT ID:** NCT02077465
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03-11
- **Primary completion:** 2014-10-27
- **Final completion:** 2014-10-27
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2020-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02077465

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02077465, "Safety, Tolerability, and Pharmacokinetics of Andecaliximab in Adults With Chronic Obstructive Pulmonary Disease (COPD)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02077465. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*